Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 66.2502
- Book/Share 26.5925
- PB 37.8259
- Debt/Equity 1.7865
- CurrentRatio 1.5463
- ROIC 0.279
- MktCap 899558538521.0
- FreeCF/Share 10.0576
- PFCF 99.7216
- PE 48.8811
- Debt/Assets 0.3698
- DivYield 0.006
- ROE 1.0226
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | LLY | UBS | -- | Buy | -- | $1250 | Jan. 7, 2026 |
| Upgrade | LLY | Daiwa Securities | Neutral | Buy | -- | $1230 | Dec. 16, 2025 |
| Reiterated | LLY | BofA Securities | -- | Buy | $1286 | $1268 | Dec. 15, 2025 |
| Reiterated | LLY | Goldman | -- | Buy | $951 | $1145 | Dec. 15, 2025 |
| Initiation | LLY | Scotiabank | -- | Sector Outperform | -- | $1165 | Nov. 13, 2025 |
| Upgrade | LLY | Leerink Partners | Market Perform | Outperform | -- | $1104 | Nov. 10, 2025 |
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
News
This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead
Published: November 21, 2025 by: Investopedia
Sentiment: Neutral
November's Wall Street obsession hasn't been AI. It's been healthcare.
Read More
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
Published: November 21, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Is GLP-1 the new AI? Drugmaker Eli Lilly briefly joined the $1 trillion market cap club.
Published: November 21, 2025 by: Market Watch
Sentiment: Positive
Eli Lilly briefly crossed the $1 trillion market cap threshold, the first drug maker to ever reach that milestone.
Read More
Eli Lilly hits $1 trillion market value, a first for a health-care company
Published: November 21, 2025 by: CNBC
Sentiment: Positive
Drugmaker Eli Lilly reached a $1 trillion market capitalization, the first health-care company in the world to join the exclusive club dominated by tech firms. The pharmaceutical giant's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and diabetes treatment Mounjaro.
Read More
ADHD pills lead to other drugs, hormone therapy guidelines have been updated and Novo Nordisk and Eli Lilly cut obesity drug prices. Read more in this week's WSJ Health newsletter:
Published: November 21, 2025 by: WSJ
Sentiment: Positive
Plus, new hormone therapy guidelines, breast-cancer pills and obesity drug price cuts, in this edition of the WSJ Health newsletter.
Read More
Novo, Lilly collaborate with Waltz Health to sell weight-loss drugs directly to employers
Published: November 21, 2025 by: Reuters
Sentiment: Positive
Digital health company Waltz Health said on Friday it has launched a program to offer popular weight-loss drugs from Novo Nordisk and Eli Lilly directly to employers, bypassing traditional drug sales channels.
Read More
Ilant Health Enhances Comprehensive Cardiometabolic Care with Direct Contracting for Obesity Management Medicine for Employers
Published: November 21, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)---- $LLY #GLP1--Ilant Health announced that it will offer employers direct contracting and transparent pricing of Eli Lilly and Company (Lilly) obesity management medicines. Employers working with Ilant Health will have the option of accessing obesity management medicines at a transparent and predictable price point starting in early 2026. Medications obtained through this collaboration will be fulfilled by a licensed mail-order pharmacy, supporting convenience, continuity, and a sea.
Read More
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
Published: November 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Baron Opportunity Fund Q3 2025 Portfolio Update
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Neutral
This quarter, we re-established a position in Arista Networks, a leading provider of high-performance networking solutions for data centers, cloud providers, and enterprises. We initiated a starter position in Synopsys after shares sold off following the company's third quarter earnings report and our in-person meeting with management. We exited our CyberArk Software Ltd. position after its acquisition by Palo Alto Networks was announced.
Read More
Lilly to participate in Citi's 2025 Global Healthcare Conference
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , Nov. 18, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Citi's 2025 Global Healthcare Conference on December 2, 2025. Ilya Yuffa, executive vice president and president Lilly USA and Global Customer Capabilities, will take part in a fireside chat at 10:30 a.m.
Read More
Eli Lilly Stock To $1,330?
Published: November 18, 2025 by: Forbes
Sentiment: Positive
Eli Lilly's stock (NYSE: LLY) has recently surged 27% over the past month, reaching a current price of $1,022. This rally is fueled by several powerful factors, including robust sales of its weight-loss drug Zepbound and diabetes drug Mounjaro, strong third-quarter financial results, and a recent government agreement regarding Medicare drug price negotiation.
Read More
Alger Growth & Income Fund Q3 2025 Portfolio Update
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Positive
Class A shares of the Alger Growth & Income Fund outperformed the S&P 500 Index during the third quarter of 2025. Apple Inc., Broadcom Inc., and Alphabet Inc. were among the top contributors to performance. Honeywell International Inc., Eli Lilly and Company, and TransDigm Group Incorporated were among the top detractors from performance.
Read More
Novo Nordisk, Eli Lilly Weight Loss Price War Heats Up. Why It's a Worry for the Stocks.
Published: November 17, 2025 by: Barrons
Sentiment: Negative
Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.
Read More
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Published: November 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Read More
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Published: November 14, 2025 by: CNBC Television
Sentiment: Positive
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Read More
Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since
Published: November 14, 2025 by: MarketBeat
Sentiment: Positive
The world's most valuable healthcare stock, Eli Lilly and Company NYSE: LLY, just dropped huge news. Like Pfizer NYSE: PFE, Lilly announced a drug pricing deal with the Trump Administration.
Read More
Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?
Published: November 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.
Read More
Novo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs
Published: November 13, 2025 by: Reuters
Sentiment: Negative
Novo Nordisk and Eli Lilly do not have a weight-loss drug partnership with telehealth website Mangoceuticals Inc , spokespeople for both companies said, rejecting a press release issued by the company on Thursday that described arrangements with the two leading drugmakers.
Read More
Can Equities Stabilize after the Government Reopens?
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
As traders position for year-end, the government shutdown is over, major market indices are filling gaps, and seasonal momentum looms.
Read More
Is Eli Lilly Stock's Run Too Hot? Here Is How It Can Crash
Published: November 12, 2025 by: Forbes
Sentiment: Neutral
Eli Lilly stock (NYSE: LLY) has surged by 21% this month, driven by strong third-quarter earnings and a favorable obesity drug pricing deal with the U.S. government. However, this recent success doesn't mean the company is invulnerable to challenges.
Read More
Why cutting drug prices is pushing Eli Lilly's stock toward an all-time high
Published: November 11, 2025 by: Market Watch
Sentiment: Positive
Even by dramatically lowering the prices of some of its medications, the drug giant is still outpacing its rivals and nearing a trillion-dollar valuation.
Read More
Lilly Up 18% in a Month: Should You Buy, Sell or Hold the Stock?
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly stock jumps 18% in a month as strong Q3 results, upgraded guidance and rising demand for Mounjaro and Zepbound fuel investor optimism.
Read More
GLP-1 prices are dropping: Who exactly will benefit?
Published: November 11, 2025 by: CNBC Television
Sentiment: Positive
CNBC's Bertha Coombs asks President Trump and his team at the White House's announcement on lower prices for Eli Lilly and Novo Nordisk's GLP-1 medications, if those new prices will extend to commercial plans. Half of Americans are covered by employer and private health plans, many of which don't cover GLP-1s for weight loss because of the cost.
Read More
Wall Street is Pounding the Table Over NVDA, RUN, LLY
Published: November 10, 2025 by: 24/7 Wall Street
Sentiment: Neutral
In addition, according to analysts at UBS, it sees Nvidia guiding fourth quarter revenue to a range of $63 billion to $64 billion.
Read More
Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease
Published: November 10, 2025 by: Reuters
Sentiment: Positive
MeiraGTx Holdings has signed a deal with Eli Lilly , potentially worth over $475 million, granting the pharma giant rights to its experimental gene therapy for a rare, inherited disorder that causes severe vision loss from birth.
Read More
Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk
Published: November 07, 2025 by: CNBC
Sentiment: Positive
President Donald Trump struck landmark deals with Eli Lilly and Novo Nordisk that could mark a turning point in access to their costly blockbuster obesity drugs. Medicare will start covering GLP-1s for obesity for certain patients for the first time beginning in mid-2026 – a shift that some experts say will open access to millions of older adults and could spur more employers and other private insurers to follow suit.
Read More
Eli Lilly, Novo Nordisk's Historic GLP-1 Pricing Deals - What Investors Need To Know
Published: November 07, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S and Eli Lilly and Company have agreed to slash US prices for Ozempic, Wegovy, Mounjaro, and Zepbound, expanding Medicare/Medicaid access. NVO's stock has dropped sharply in 2025, but the new deal could boost long-term revenue by increasing drug accessibility and wiping out compounded competition. Despite price cuts, LLY's strong US manufacturing presence and blockbuster tirzepatide sales position it for continued growth and potential $1T market cap.
Read More
LLY's GLP-1 Duo Boosts Sales Amid Rising Demand for Obesity Drugs
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly's Mounjaro and Zepbound continue to power growth as new launches boost momentum amid rising obesity competition.
Read More
Eli Lilly and Novo Nordisk lower GLP-1 drug costs in new deal with Trump.
Published: November 06, 2025 by: Yahoo Finance
Sentiment: Positive
About Yahoo Finance: Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life. - Get the latest news and data at finance.yahoo.com - Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO) - Follow Yahoo Finance on social: X: http://twitter.com/YahooFinance Instagram: https://www.instagram.com/yahoofinance/?hl=en TikTok: https://www.tiktok.com/@yahoofinance?lang=en Facebook: https://www.facebook.com/yahoofinance/ LinkedIn: https://www.linkedin.com/company/yahoo-finance
Read More
Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk
Published: November 06, 2025 by: CNBC
Sentiment: Positive
President Donald Trump struck landmark deals with Eli Lilly and Novo Nordisk to slash the prices of their blockbuster weight loss drugs. Under the agreements, the monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350, depending on the dosage and insurance coverage a patient has.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000